The results of our open-label, prospective 4-week trial suggest that the 5-HT1A receptor agonist, buspirone, given orally for 4 weeks, significantly increases the LES resting pressure by 41 % to 220 % over the baseline values in almost 70 % of patients with SSc. This evidence concerns the gene HTR1A and systemic sclerosis.